Patents Examined by Shanon A. Foley
-
Patent number: 11654191Abstract: The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.Type: GrantFiled: March 22, 2017Date of Patent: May 23, 2023Assignee: Intervet Inc.Inventors: Melanie Sno, Maarten Hendrik Witvliet, Vicky Fachinger
-
Patent number: 11655284Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: June 23, 2022Date of Patent: May 23, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 11648304Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.Type: GrantFiled: November 5, 2018Date of Patent: May 16, 2023Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Holli Giebler, Whitney Baldwin, Hansi Dean, Claire Y. H. Kinney
-
Patent number: 11643641Abstract: A method and composition for inactivating both naked genetic material such as RNA and DNA and inactivating mechanical delivery vectors in a treatment space external of the human body. To practice the method, apply a mist of lipid molecule degrading agent effective against viral membranes with lipid molecules. Then apply an inactivator of spike proteins and other viral residues. Next, reduce the threat of transmitting genetic material by applying inactivators of mechanical transport vectors such as mold, yeast, and bacteria. Further, pretreat the treating space to receive enzymatic agents by applying a surface detoxifying agent in quantity sufficient to inactivate substances detrimental to enzymes that break the naked viral genetic material. Then, apply preparatory enzymes that degrade microorganisms and their cellular components. Finally, apply enzymes for breaking the naked viral genetic material, as present.Type: GrantFiled: February 25, 2022Date of Patent: May 9, 2023Inventor: Malireddy S. Reddy
-
Patent number: 11643640Abstract: Certain embodiments are directed to an improved RVF vaccine for human use, and method for producing the same.Type: GrantFiled: October 9, 2020Date of Patent: May 9, 2023Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: Tetsuro Ikegami
-
Patent number: 11629181Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: June 23, 2022Date of Patent: April 18, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 11629172Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.Type: GrantFiled: December 19, 2019Date of Patent: April 18, 2023Assignee: Pfizer Inc.Inventors: Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
-
Patent number: 11628214Abstract: The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.Type: GrantFiled: March 26, 2020Date of Patent: April 18, 2023Inventors: Veljko Nikolin, Egbert Siegfried Mundt, Fernando Rodriguez Gonzalez, Laia Bosch Camos, Javier Alonso Collado Miguens
-
Patent number: 11629338Abstract: Disclosed is a second-order culture method for producing a suspended Vero cell vaccine, wherein same comprises the following steps: suspension culture growth of Vero cells, inoculation of a virus, dilution or addition of a production medium, secondary growth of cells, and optionally harvesting and purifying the virus fluid to produce the vaccine.Type: GrantFiled: November 9, 2017Date of Patent: April 18, 2023Assignee: JIANSHUN BIOSCIENCES CO., LTD.Inventors: Shijun Cai, Ruijuan Hou
-
Patent number: 11623004Abstract: Disclosed herein are compositions for vaccination against respiratory syncytial virus (RSV) comprising a RSV F polypeptide stabilized in a prefusion conformation and an inulin adjuvant. Also disclosed herein are methods of vaccinating a subject against a respiratory syncytial virus (RSV) infection comprising administering to the subject an RSV F polypeptide stabilized in a prefusion conformation and an inulin adjuvant. In some embodiments, the subject is a female, and the method can reduce RSV infection in the subject and/or in the offspring of the subject. In some embodiments, the method decreases vaccine-enhanced respiratory disease (VERD) and/or eosinophilia in the subject or offspring of the subject.Type: GrantFiled: March 15, 2019Date of Patent: April 11, 2023Assignees: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, CALDER BIOSCIENCES INC., VAXINE PTY LTDInventors: Kerry McGarr Empey, Nikolai Petrovsky, Christopher Marshall
-
Patent number: 11619589Abstract: A method and a system of detecting, identifying and quantifying an analyte, for example coronavirus, in a specimen comprising, comprising: apportioning the suspended specimen into one or more test samples; optionally adding a reagent to the test samples; and applying an electric field with a first magnitude and with a second magnitude over the test samples for a selected period of time. The second magnitude should be higher than the first magnitude. The method and system further comprises: measuring electrical properties of said one or more test samples in response to said applied electric field for said first magnitude and for said second magnitude over said period of time; identifying characteristics of said electrical properties responses; and determining the presence, the identification and/or the quantity of coronavirus based on the characteristics of said electrical properties responses to said first magnitude and to said second magnitude of the applied electric field.Type: GrantFiled: October 29, 2021Date of Patent: April 4, 2023Assignee: United Arab Emirates UniversityInventor: Mahmoud F. Y. Al Ahmad
-
Patent number: 11613561Abstract: Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.Type: GrantFiled: March 18, 2022Date of Patent: March 28, 2023Assignee: TIBA BIOTECH, LLCInventors: Jasdave S Chahal, Justine S McPartlan
-
Patent number: 11608361Abstract: Nucleic acids encoding norovirus VP1 fusion proteins and VLPs comprising the norovirus VP1 fusion proteins are provided. Methods for norovirus VP1 fusion protein and norovirus VLP production in plants are also described. The VP1 fusion protein comprises, a first sequence encoding an S domain derived from a first norovirus strain, and a second sequence encoding a P domain derived from a second norovirus strain.Type: GrantFiled: March 23, 2018Date of Patent: March 21, 2023Assignee: MEDICAGO INC.Inventors: Pierre-Olivier Lavoie, Marc-Andre D'Aoust
-
Patent number: 11602557Abstract: The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines.Type: GrantFiled: August 22, 2018Date of Patent: March 14, 2023Assignee: Cure Vac SEInventors: Benjamin Petsch, Edith Jasny
-
Patent number: 11603552Abstract: The present invention relates to a method for detecting a pathogen in cellular lysate by measuring pathogen-specific enzyme activity. The method comprises contacting the cellular lysate with a substrate the pathogen of interest recognizes and modifies, and obtaining a measurable, recordable, signal. The method may comprise detection of SARS-CoV viruses using the activity of SARS PLpro enzyme in tongue scrape lysate as a readout.Type: GrantFiled: July 20, 2021Date of Patent: March 14, 2023Assignee: Mesa Photonics, LLCInventors: Frauke Henrike Rininsland, Daniel James Kane
-
Patent number: 11596681Abstract: The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site UL43. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.Type: GrantFiled: March 19, 2019Date of Patent: March 7, 2023Inventors: Alice Mundt, Andreas Gallei, Kristina Rehmet
-
Patent number: 11591372Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.Type: GrantFiled: May 18, 2020Date of Patent: February 28, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
-
Patent number: 11576960Abstract: Disclosed are vaccines capable of achieving protection against RSV while avoiding vaccine-enhanced disease (VED). In particular, vaccine constructs have been molecularly designed and genetically engineered to comprise RSV fusion (F) protein displayed on the surface of a particle, such as a virus-like particles (VLP) and low temperature-prepared split RSV. In some embodiments, the RSV F protein is in a pre-fusion F conformation. Also disclosed a variants and combinations of split RSV and RSV F DNA vaccine with pre-fusion F and enhanced efficacy. In addition, disclosed split RSV vaccines containing pre-fusion F conformation and combination adjuvants MPL and CpG.Type: GrantFiled: March 29, 2019Date of Patent: February 14, 2023Assignee: Georgia State University Research Foundation, Inc.Inventors: Sang-Moo Kang, Youri Lee, Eunju Ko, Young-Man Kwon, Ki-Hye Kim
-
Patent number: 11576961Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: GrantFiled: March 15, 2018Date of Patent: February 14, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
-
Patent number: 11571472Abstract: Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.Type: GrantFiled: June 12, 2015Date of Patent: February 7, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Ann-Muriel Steff, Jean-Francois Toussaint, Alessandra Vitelli